Literature DB >> 16943419

Multiple features contribute to the use of the immunoglobulin M secretion-specific poly(A) signal but are not required for developmental regulation.

Martha L Peterson1, Gina L Bingham, Clarissa Cowan.   

Abstract

The secretory-specific poly(A) signal (mus) of the immunoglobulin mu gene plays a central role in regulating alternative RNA processing to produce RNAs that encode membrane-associated and secreted immunoglobulins. This poly(A) signal is in direct competition with a splice reaction, and regulation requires that these two reaction efficiencies be balanced. The mus poly(A) signal has several unique sequence features that may contribute to its strength and regulation. Site-directed mutations and small internal deletions made in the intact mu gene show that an extensive AU/A-rich sequence surrounding AAUAAA enhances signal use and that, of the two potential downstream GU-rich elements, both of which appear suboptimally located, only the proximal GU-rich sequence contributes substantially to use of this signal. A GU-rich sequence placed at a more standard location did not improve mus poly(A) signal use. All mu genes tested that contained modified mus poly(A) signals were developmentally regulated, indicating that the GU-rich sequences, the sequences between them previously identified as suboptimal U1A binding sites, and an upstream suboptimal U1A site do not contribute to mu mRNA processing regulation. Expression of wild-type and modified mu genes in HeLa cells overexpressing U1A also failed to demonstrate that U1A contributes to mus poly(A) signal regulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16943419      PMCID: PMC1592873          DOI: 10.1128/MCB.00889-06

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  47 in total

Review 1.  Formation of mRNA 3' ends in eukaryotes: mechanism, regulation, and interrelationships with other steps in mRNA synthesis.

Authors:  J Zhao; L Hyman; C Moore
Journal:  Microbiol Mol Biol Rev       Date:  1999-06       Impact factor: 11.056

2.  The synthesis and processing of the messenger RNAs specifying heavy and light chain immunoglobulins in MPC-11 cells.

Authors:  U Schibler; K B Marcu; R P Perry
Journal:  Cell       Date:  1978-12       Impact factor: 41.582

3.  Recognition of GU-rich polyadenylation regulatory elements by human CstF-64 protein.

Authors:  José Manuel Pérez Cañadillas; Gabriele Varani
Journal:  EMBO J       Date:  2003-06-02       Impact factor: 11.598

4.  An RNA polymerase pause site is associated with the immunoglobulin mus poly(A) site.

Authors:  Martha L Peterson; Shannon Bertolino; Frankie Davis
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

5.  B-cell and plasma-cell splicing differences: a potential role in regulated immunoglobulin RNA processing.

Authors:  Shirley R Bruce; R W Cameron Dingle; Martha L Peterson
Journal:  RNA       Date:  2003-10       Impact factor: 4.942

6.  U1A inhibits cleavage at the immunoglobulin M heavy-chain secretory poly(A) site by binding between the two downstream GU-rich regions.

Authors:  Catherine Phillips; Niseema Pachikara; Samuel I Gunderson
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

7.  Regulated production of mu m and mu s mRNA requires linkage of the poly(A) addition sites and is dependent on the length of the mu s-mu m intron.

Authors:  M L Peterson; R P Perry
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

8.  Cell-type specificity of immunoglobulin gene expression is regulated by at least three DNA sequence elements.

Authors:  R Grosschedl; D Baltimore
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

9.  Correct transcription of an immunoglobulin kappa gene requires an upstream fragment containing conserved sequence elements.

Authors:  F G Falkner; H G Zachau
Journal:  Nature       Date:  1984 Jul 5-11       Impact factor: 49.962

10.  Sequence determinants in human polyadenylation site selection.

Authors:  Matthieu Legendre; Daniel Gautheret
Journal:  BMC Genomics       Date:  2003-02-25       Impact factor: 3.969

View more
  7 in total

1.  Coordination of RNA Polymerase II Pausing and 3' End Processing Factor Recruitment with Alternative Polyadenylation.

Authors:  Becky Fusby; Soojin Kim; Benjamin Erickson; Hyunmin Kim; Martha L Peterson; David L Bentley
Journal:  Mol Cell Biol       Date:  2015-11-02       Impact factor: 4.272

2.  A Lentiviral Vector Allowing Physiologically Regulated Membrane-anchored and Secreted Antibody Expression Depending on B-cell Maturation Status.

Authors:  Floriane Fusil; Sara Calattini; Fouzia Amirache; Jimmy Mancip; Caroline Costa; Justin B Robbins; Florian Douam; Dimitri Lavillette; Mansun Law; Thierry Defrance; Els Verhoeyen; François-Loïc Cosset
Journal:  Mol Ther       Date:  2015-08-18       Impact factor: 11.454

3.  Polypyrimidine tract binding protein prevents activity of an intronic regulatory element that promotes usage of a composite 3'-terminal exon.

Authors:  Vincent Anquetil; Caroline Le Sommer; Agnès Méreau; Sandra Hamon; Hubert Lerivray; Serge Hardy
Journal:  J Biol Chem       Date:  2009-09-17       Impact factor: 5.157

Review 4.  A day in the life of the spliceosome.

Authors:  A Gregory Matera; Zefeng Wang
Journal:  Nat Rev Mol Cell Biol       Date:  2014-02       Impact factor: 94.444

Review 5.  Engineered proteins with Pumilio/fem-3 mRNA binding factor scaffold to manipulate RNA metabolism.

Authors:  Yang Wang; Zefeng Wang; Traci M Tanaka Hall
Journal:  FEBS J       Date:  2013-06-24       Impact factor: 5.542

Review 6.  Mechanisms controlling production of membrane and secreted immunoglobulin during B cell development.

Authors:  Martha L Peterson
Journal:  Immunol Res       Date:  2007       Impact factor: 4.505

7.  Discovery of novel human transcript variants by analysis of intronic single-block EST with polyadenylation site.

Authors:  Pingzhang Wang; Peng Yu; Peng Gao; Taiping Shi; Dalong Ma
Journal:  BMC Genomics       Date:  2009-11-12       Impact factor: 3.969

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.